Alaunos Therapeutics (TCRT) Net Margin (2016 - 2025)
Historic Net Margin for Alaunos Therapeutics (TCRT) over the last 13 years, with Q1 2025 value amounting to 54600.0%.
- Alaunos Therapeutics' Net Margin rose 1196000000.0% to 54600.0% in Q1 2025 from the same period last year, while for Sep 2025 it was 67883.33%, marking a year-over-year increase of 1322333300.0%. This contributed to the annual value of 48120.0% for FY2024, which is 6756400000.0% up from last year.
- Per Alaunos Therapeutics' latest filing, its Net Margin stood at 54600.0% for Q1 2025, which was up 1196000000.0% from 18875.0% recorded in Q4 2024.
- Alaunos Therapeutics' Net Margin's 5-year high stood at 312.78% during Q3 2022, with a 5-year trough of 794900.0% in Q4 2023.
- For the 5-year period, Alaunos Therapeutics' Net Margin averaged around 197999.68%, with its median value being 70122.73% (2025).
- As far as peak fluctuations go, Alaunos Therapeutics' Net Margin plummeted by 2000000000bps in 2023, and later surged by 2000000000bps in 2024.
- Alaunos Therapeutics' Net Margin (Quarter) stood at 590350.0% in 2021, then surged by 85bps to 85645.45% in 2022, then crashed by -828bps to 794900.0% in 2023, then soared by 98bps to 18875.0% in 2024, then tumbled by -189bps to 54600.0% in 2025.
- Its Net Margin stands at 54600.0% for Q1 2025, versus 18875.0% for Q4 2024 and 29150.0% for Q2 2024.